Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun 4:16:1560295.
doi: 10.3389/fimmu.2025.1560295. eCollection 2025.

Efficacy and safety of combined loratadine and mometasone furoate therapy in allergic rhinitis patients

Hui Yong #  1 , Lingling Di #  1 , Zhikai Wang  1 , Jing Yang  1 , Pei Yang  1 , Xiaoping Gao  1
Affiliations
Randomized Controlled Trial

Efficacy and safety of combined loratadine and mometasone furoate therapy in allergic rhinitis patients

Hui Yong et al. Front Immunol. .

Abstract

Objective: This study seeks to assess the effectiveness and safety of a combination treatment involving loratadine and mometasone furoate for patients suffering from allergic rhinitis (AR). Additionally, it explores the risk factors contributing to treatment failure, providing a theoretical basis for identifying safer and more effective AR treatments.

Methods: A prospective study was carried out between January 1, 2021, and April 1, 2023, involving 116 patients with allergic rhinitis (AR) who were treated at our outpatient clinic. Participants were randomly divided into two groups: the control group (n=58), which received loratadine alone, and the study group (n=58), which received a combination of loratadine and mometasone furoate. Outcome measures included nasal symptom scores and serological markers, assessed before and after the treatment period. The effectiveness of the treatment was assessed using nasal symptom scores.

Results: Post-treatment assessments showed that both nasal symptom scores and serological markers were significantly lower in the study group compared to the control group (P<0.05). Additionally, the overall response rate was markedly higher in the study group (P<0.05). There were no significant differences in the total incidence of adverse reactions between the two groups (P>0.05).

Conclusion: The combination of loratadine and mometasone furoate effectively alleviates clinical symptoms in patients with allergic rhinitis while demonstrating a favorable safety profile, making it a promising option for clinical use.

Keywords: allergic rhinitis; combination therapy; efficacy; loratadine; mometasone furoate.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

References

    1. Bousquet J, Anto JM, Bachert C. Allergic rhinitis. Nat Rev Dis Primers. (2020) 6:95. doi: 10.1038/s41572-020-00227-0 - DOI - PubMed
    1. Siddiqui ZA, Walker A, Pirwani MM. Allergic rhinitis: diagnosis and management. Br J Hosp Med (London England: 2005). (2022) 83:1–9. doi: 10.12968/hmed.2021.0570 - DOI - PubMed
    1. Okubo K, Kurono Y, Ichimura K, Enomoto T, Okamoto Y, Kawauchi H, et al. Japanese Society of A: Japanese guidelines for allergic rhinitis 2020. Allergology international: Off J Japanese Soc Allergology. (2020) 69:331–45. doi: 10.1016/j.alit.2020.04.001 - DOI - PubMed
    1. Wang H, Huang H, Liu X. Study on airborne pollen surveillance and allergen profile of allergic rhinitis in hohhot. Chin J Ophthalmol Otorhinolaryngol. (2023) 23:55–9.
    1. Rizzi A, Parrinello G, De Corso E. Mometasone furoate in non-allergic rhinitis: A real-life italian study. J Pers Med. (2022) 12:1179. doi: 10.3390/jpm12071179 - DOI - PMC - PubMed

Publication types

LinkOut - more resources